Ziopharm Oncology to Present at the Jefferies 2020 Healthcare Conference on June 3, 2020
Rhea-AI Summary
BOSTON, May 27, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that CEO Laurence Cooper will participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on June 3, 2020, at 3:00 p.m. ET. Investors can access the live webcast and the archived recording via the "Investors" section of the Ziopharm website. Ziopharm focuses on developing innovative cell and gene therapies aimed at treating solid tumors through its unique non-viral gene transfer platform and strategic partnerships with major cancer research institutions.
Positive
- None.
Negative
- None.
News Market Reaction – ZIOP
In the trading session that priced this news, ZIOP gained 7.06%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020, at 3:00 p.m. ET.
To access the live webcast presentation, or the subsequent archived recording, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com
Investor Relations Contacts:
Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E: ctaylor@ziopharm.com
LifeSci Advisors:
Mike Moyer
Managing Director
T: 617.308.4306
E: mmoyer@lifesciadvisors.com
Media Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932
E: pbursey@lifescicomms.com